Business Wire

Agendia Appoints Farida Peters-Abbadi as Vice President of Marketing

Share

Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced the appointment of seasoned diagnostic and medical device executive Farida Peters-Abbadi as Vice President of Marketing, effective April 4, 2022.

“Farida is an exciting addition to our executive team as we focus on accelerating commercial growth and introducing new groundbreaking products and services for breast cancer patients and their physicians,” said Betsy Hanna, Executive Vice President and Chief Commercial Officer at Agendia. “Not only has she consistently driven commercial growth and structural evolution in other pioneering diagnostic and device companies, she’s done so with a dynamism that we feel is requisite for success at and for Agendia. Her experience, specifically in establishing women’s health companies and launching first-to-market products, will help our teams accelerate the achievement of Agendia’s goals in the near future.”

Most recently, Ms. Peters-Abbadi served as President and Chief Commercial Officer at Mirvie, an early-stage liquid biopsy diagnostic company, where she led the commercial, regulatory, and clinical strategy, developed the go-to-market and launch plans, and secured funding for a capital raise. Prior to that, she held a P&L leadership role as Vice President of Sales and Marketing at Renovia, an early-stage medical device company, where she was responsible for healthcare provider marketing, direct-to-consumer marketing, sales and customer service, partnerships, and commercial operations, ultimately delivering 80% year-over-year revenue growth.

Ms. Peters-Abbadi also held a series of sales and sales management roles at ViaCell before joining PerkinElmer, where over the course of 12 years she rose to the level of Director of Marketing and led the launch plans for non-invasive prenatal testing that achieved a 25% increase in revenue. Her education includes double law degrees from McGill University, an Executive Master of Business Administration from Northwestern University’s Kellogg School of Management and a Bachelor of Arts from Binghamton University.

“My passion for women’s health is rooted in the conviction that women deserve effective solutions that prioritize their quality of life. My aim is to integrate my expertise as a marketing strategist into the robust efforts already underway at Agendia,” said Ms. Peters-Abbadi. “The combination of established products like MammaPrint and BluePrint, and a pipeline of products with the potential to transform the standard of care and impact the lives of more patients worldwide, makes for a natural fit. I look forward to bringing innovation to Agendia’s ongoing positive commercial momentum and accelerating its success.”

Ms. Peters-Abbadi’s appointment comes as the Agendia Board and management team adds to the strong executive and operational talent in the company at all levels. The company believes this dedication translates into exceptional science, actionable and transformative research, and bringing innovative new products to market to ensure patients with breast cancer, their families, and their physicians have access to the information they need to make the best decisions about the treatment journey.

About Agendia

Agendia is a mission-driven, commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.

MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.

For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media

Terri Clevenger
ICR Westwicke Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Collecting Sensitive Data Without User Consent: 24 Leading Online Pharmacies From Nordic Countries Fail GDPR Requirements – Usercentrics Reports18.5.2022 08:01:00 CEST | Press release

Analysis by Usercentrics shows: Over 80% of scanned domains from Denmark, Sweden and Norway are not GDPR compliant, setting at least one non-necessary cookie without user consent. Sweden ranks highest with an average of 26 non-necessary cookies set. In total 89% of the most popular online pharmacies in the EU do not meet GDPR requirements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517006345/en/ Lack of Data Protection on EU Pharma Webshops: The majority of websites do not operate in a privacy-compliant manner - analysis by Usercentrics shows. (Graphic: Business Wire) Pharmacy webshops constantly process personal data of their visitors, while selling privacy-sensitive products such as antidepressants, diabetes medicines or addiction treatments. Usercentrics scanned the 150 most-used pharmacy webstores in the EU, analyzing the extent to which website operators are complying with the General Data Protection Regulation (

Banks Shift to Eco-friendly Solutions Supported by Innovative Thales Cards, Certified Sustainable by Mastercard18.5.2022 08:00:00 CEST | Press release

The amount of plastic used to produce payment cards every year is equivalent to the weight of 125 Statues of Liberty1. With environmental challenges now a growing, global concern, Thales, the leader in high tech security, has developed solutions for a greener world, recently certified by Mastercard’s Sustainable Card Program. To date, Thales has deployed 30 million eco-friendly payment cards for banks and card issuers that address consumer concerns without compromising the user experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005012/en/ (Photo: Thales) All eco-friendly cards offered by Thales are made with innovative and sustainable components. For example, one solution is a card made from 85% PLA (polylactic acid), which is produced from corn. Another innovative approach reduces the amount of new plastic while fighting sea pollution, with a card made of Ocean Plastic® collected by Parley for the Oceans. This

Anterra Capital: Pandemic and Food Price Inflation Fuel Investor Interest to Accelerate Transformation of the Food and Ag Sector18.5.2022 07:00:00 CEST | Press release

A crushing pandemic and, more recently, the Ukraine war have convinced investors more than ever that the world needs to radically change how it produces, distributes and consumes food, says Adam Anders, managing partner of the international food and agriculture specialist venture capital firm Anterra Capital (“Anterra”). Anders: “The pandemic highlighted the fragility and adverse health impacts of our current food system: soaring prices, empty shelves in stores; the fact that unhealthy diets are a major risk factor for getting Covid; that the way we treat farm animals could trigger the next pandemic. Post our final closing, the devastating impact of the Ukraine War on the global food supply has increased the awareness among investors even further. This, plus our focus on deploying proven biotech and digital solutions to shake up the lagging Food and Ag-sector, go a long way in explaining the higher than expected interest in our second fund.” Anterra is proud to announce the closing of

US Streaming Technology Giant Conviva Launches Full-Scale Continuous Measurement Analytics in Japan18.5.2022 03:00:00 CEST | Press release

Conviva (Headquartered at Foster City, California, USA; Japan Office: Chiyoda-ku, Tokyo; hereinafter referred to as Conviva or the Company), which provides continuous measurement analytics through real-time, server side sessionization of video streaming data, today announced the opening of the Japan office, which will serve as a base for sales and customer support in the rapidly-growing Japanese market. The Company also released a current State of Streaming Report for Japan highlighting key streaming trends in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517006275/en/ Conviva State of Streaming Japan Report (Graphic: Business Wire) “Conviva invented continuous measurement analytics for streaming video and has been driving the development of the global market including Japan with over 58 technology patents over the past decade,” comments Conviva CEO Keith Zubchevich. “Today, we are pleased to announce the est

Starr Insurance Companies Expands in Thailand17.5.2022 22:33:00 CEST | Press release

Starr Insurance Companies (Starr) announced an agreement with FPG Insurance Holdings Limited (HK) (FPG) and local Thai shareholders to purchase FPG Insurance Public Company Limited (FPG Thailand), a Thai non-life insurance company, together with local Thai parties. Starr’s investment will be held by its Bermuda insurance company, Starr Insurance & Reinsurance Limited. The transaction is expected to close in the second quarter of 2022, subject to certain customary closing conditions, including any necessary regulatory approvals. “Thailand is an important, fast-growing insurance market — one of the cornerstones of the Southeast Asia economy,” said Maurice R. Greenberg, Starr’s Chairman & CEO. “Asia is both commercially and culturally important to Starr, as we trace our roots to an American-owned company founded in Shanghai more than 100 years ago. We look forward to serving the needs of local Thai companies and consumers through this new insurance capability.” David Zuellig, FPG regional

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom